Immune checkpoint inhibitors in mesothelioma: a turning point

Ceresoli, Giovanni Luca; Pasello, Giulia

doi:10.1016/s0140-6736(21)00147-1

Cited by 14 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The application of immune checkpoint inhibitors has been a novel approach to and research hotspot in tumor immunotherapy in recent years, and has also shown considerable efficacy in the treatment of several tumors ( 66 – 68 ). First-generation immune checkpoint blockade tumor immunotherapy based on antibodies acts by blocking the interaction between receptors and/or ligand molecules, such as CTLA-4 and PD-1, that are involved in T-cell activation or reduced function ( 8 ).…”

Section: Immune Checkpoints and Tumor Immunotherapymentioning

confidence: 99%

Role of the tumor immune microenvironment in tumor immunotherapy (Review)

et al. 2021

View full text Add to dashboard Cite

Tumor immunotherapy is considered to be a novel and promising therapy for tumors and it has recently become a hot research topic. The clinical success of tumor immunotherapy has been notable, but it has been less than totally satisfactory because tumor immunotherapy has performed poorly in numerous patients although it has shown appreciable efficacy in some patients. A minority of patients demonstrate durable responses but the majority of patients do not respond to tumor immunotherapy as the tumor immune microenvironment is different in different patients for different tumor types. The success of tumor immunotherapy may be affected by the heterogeneity of the tumor immune microenvironment and its components, as these vary widely during neoplastic progression. The deepening of research and the development of technology have improved our understanding of the complexity and heterogeneity of the tumor immune microenvironment and its components, and their effects on response to tumor immunotherapy. Therefore, investigating the tumor immune microenvironment and its components and elucidating their association with tumor immunotherapy should improve the ability to study, predict and guide immunotherapeutic responsiveness, and uncover new therapeutic targets.

show abstract

Section: Immune Checkpoints and Tumor Immunotherapymentioning

confidence: 99%

Role of the tumor immune microenvironment in tumor immunotherapy (Review)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Thus, early detection of mesothelioma, multi-channel interventions and novel targeted treatments are urgently needed to be developed. Of note, recently available data support a possible role of miRNAs and DNA methylation in the etiology of mesothelioma and suggest their potential as biomarkers for the early diagnosis and even for the screening of an at a high-risk population of asbestos-exposed individuals [29][30][31][32] . Besides, several novel therapeutic agents are under investigation in recent years, such as targeted therapies and immunotherapies, which may provide further treatment options and improve clinical outcomes for mesothelioma in the future [33][34] .…”

Section: Discussionmentioning

confidence: 99%

Global Magnitude and Temporal Trend of Mesothelioma Burden Along with the Contribution of Occupational Asbestos Exposure in 204 Countries and Territories From 1990 to 2019: Results from the Global Burden of Disease Study 2019

Han

Zhang

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Understanding the annual incidence, mortality, and disability-adjusted life-years (DALYs) for mesothelioma globally provides essential foundations for cancer control, policy decisions and resource allocation. Materials and methods Complying with the Global Burden of Disease Study 2019, we extracted the data of incidences, deaths and DALYs in 204 countries and territories from 1990 to 2019. Average annual percentage changes were used to quantify the temporal trends in mesothelioma burden. Besides, the population attributable fractions of the risk factor of mesothelioma were also estimated. Results Globally, 34511 (95% uncertainty intervals[UI]: 31199, 37771) incident cases, 29251 (95%UI: 26668, 31006) deaths and 668104 (95%UI: 608269, 716475) DALYs of mesothelioma were estimated in 2019. The age-standardized rates of incidence, mortality and DALYs all showed a slightly declining trend over the past 30 years, but the latest absolute number of mesothelioma burden almost doubled since 1990. The age-standardized burden of mesothelioma among men was around 3 times more than women in 2019, which decreased among women while remained stable among men. The burden rate decreased among the population aged under 70 years, but increased among the population aged over 80 years, especially in the High socio-demographic index (SDI) region. The age-standardized DALYs rate (ASDR) of mesothelioma attributable to occupational asbestos exposure in 2019 was positively associated with SDI at the national levels (ρ = 0.3105, P = 6.2e-06). Conclusion This study depicted a continuous increase in incidences, deaths and DALYs of mesothelioma globally over the past 30 years. Controlling occupational asbestos exposure will reduce the mesothelioma burden, especially for higher SDI regions.

show abstract

“…The effectiveness of systemic anticancer therapy for MPM has been limited to date, although there is increasing interest and data supporting the role of immunotherapy with immune checkpoint inhibition [69,70]. Single agent chemotherapy is ineffective.…”

Section: Treatment Of Mesotheliomamentioning

confidence: 99%

Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma

Brims

2021

Cancers

View full text Add to dashboard Cite

Mesothelioma is a cancer predominantly of the pleural cavity. There is a clear association of exposure to asbestos with a dose dependent risk of mesothelioma. The incidence of mesothelioma in different countries reflect the historical patterns of commercial asbestos utilisation in the last century and predominant occupational exposures mean that mesothelioma is mostly seen in males. Modern imaging techniques and advances in immunohistochemical staining have contributed to an improved diagnosis of mesothelioma. There have also been recent advances in immune checkpoint inhibition, however, mesothelioma remains very challenging to manage, especially considering its limited response to conventional systemic anticancer therapy and that no cure exists. Palliative interventions and support remain paramount with a median survival of 9–12 months after diagnosis. The epidemiology and diagnosis of mesothelioma has been debated over previous decades, due to a number of factors, such as the long latent period following asbestos exposure and disease occurrence, the different potencies of the various forms of asbestos used commercially, the occurrence of mesothelioma in the peritoneal cavity and its heterogeneous pathological and cytological appearances. This review will describe the contemporary knowledge on the epidemiology of mesothelioma and provide an overview of the best clinical practice including diagnostic approaches and management.

show abstract

Immune checkpoint inhibitors in mesothelioma: a turning point

Cited by 14 publications

References 12 publications

Role of the tumor immune microenvironment in tumor immunotherapy (Review)

Role of the tumor immune microenvironment in tumor immunotherapy (Review)

Global Magnitude and Temporal Trend of Mesothelioma Burden Along with the Contribution of Occupational Asbestos Exposure in 204 Countries and Territories From 1990 to 2019: Results from the Global Burden of Disease Study 2019

Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma

Contact Info

Product

Resources

About